[go: up one dir, main page]

NO20065502L - Farmasoytiske sammensetninger. - Google Patents

Farmasoytiske sammensetninger.

Info

Publication number
NO20065502L
NO20065502L NO20065502A NO20065502A NO20065502L NO 20065502 L NO20065502 L NO 20065502L NO 20065502 A NO20065502 A NO 20065502A NO 20065502 A NO20065502 A NO 20065502A NO 20065502 L NO20065502 L NO 20065502L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
relates
present
glycopyrrolate
antimuscarinic
Prior art date
Application number
NO20065502A
Other languages
English (en)
Inventor
David Morton
Martin Shott
Rebecca Davies
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065502(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20065502L publication Critical patent/NO20065502L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår farmasøytiske preparater omfattende det antimuskarine middel glykopyrrolat, for eksempel saltet glykopyrroniumbromid. Spesielt angår foreliggende oppfinnelse tørrpulver-preparater som viser forbedret stabilitet over tid og metoder for å produsere disse.
NO20065502A 2004-04-30 2006-11-29 Farmasoytiske sammensetninger. NO20065502L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
PCT/EP2005/051980 WO2005105043A2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20065502L true NO20065502L (no) 2007-01-24

Family

ID=32408337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065502A NO20065502L (no) 2004-04-30 2006-11-29 Farmasoytiske sammensetninger.

Country Status (26)

Country Link
US (1) US20080063719A1 (no)
EP (3) EP1755555B1 (no)
JP (2) JP5000483B2 (no)
KR (1) KR101287919B1 (no)
CN (3) CN102008453A (no)
AU (2) AU2005237266B2 (no)
BR (1) BRPI0510500B8 (no)
CA (1) CA2563760C (no)
CY (6) CY1113069T1 (no)
DK (2) DK2422766T3 (no)
ES (2) ES2388289T3 (no)
GB (1) GB0409703D0 (no)
HU (4) HUE025463T2 (no)
IL (2) IL178651A (no)
LT (1) LTC2422766I2 (no)
LU (2) LU92176I2 (no)
MX (2) MXPA06012493A (no)
NO (1) NO20065502L (no)
NZ (1) NZ550479A (no)
PL (2) PL1755555T3 (no)
PT (2) PT2422766E (no)
RU (1) RU2396943C2 (no)
SG (3) SG152292A1 (no)
SI (2) SI1755555T1 (no)
WO (1) WO2005105043A2 (no)
ZA (1) ZA200609350B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
BRPI0820745A2 (pt) * 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos
RU2482838C2 (ru) * 2007-12-13 2013-05-27 Новартис Аг Органические соединения
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
SI2400950T1 (sl) 2009-02-26 2019-09-30 Glaxo Group Limited Farmacevtske forlmulacije, ki obsegajo 4-((1 R)-2-((6-(2-((2,6- diklorobenzil)oksi)etoksi)heksil)amino)-1-hidroksietil)-2- (hidroksimetil)fenol
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
US20130028977A1 (en) * 2010-03-31 2013-01-31 Glenmark Pharmaceuticals Limited Pharmaceutical powder composition for inhalation
MX336414B (es) 2010-04-01 2016-01-19 Chiesi Farma Spa Proceso de preparacion de particulas portadoras para polvos secos para inhalacion.
AU2011244384B2 (en) * 2010-04-21 2016-06-23 Chiesi Farmaceutici S.P.A. "Process for providing particles with reduced electrostatic charges"
EP2611422B1 (en) 2010-08-31 2018-10-31 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP2954888A1 (en) 2010-08-31 2015-12-16 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
SG11201506789PA (en) 2013-02-28 2015-09-29 Dermira Inc Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
PT3191081T (pt) * 2014-09-09 2020-05-29 Vectura Ltd Formulação que compreende glicopirrolato, método e equipamento
CN107106514A (zh) * 2014-10-16 2017-08-29 梯瓦优质制药产品研发股份有限公司 干燥粉末配制剂
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
CA3016488C (en) 2016-03-08 2023-04-11 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
MX389563B (es) 2016-03-08 2025-03-20 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.
ES2805434T3 (es) 2016-07-29 2021-02-12 Inke Sa Procedimiento de estabilización de tamaño de partícula
CA3037092C (en) 2016-09-19 2022-06-21 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
ES3009923T3 (en) * 2017-03-15 2025-03-31 Vectura Ltd Method and formulation
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
CA3085544A1 (en) 2017-12-11 2019-06-20 Mereo Biopharma 1 Limited Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
WO2019116021A1 (en) 2017-12-11 2019-06-20 Mereo Biopharma 1 Limited Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
DE59914603D1 (de) * 1998-11-13 2008-02-14 Jagotec Ag Multidosis-Trockenpulverinhalator mit Pulverreservoir
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US7744855B2 (en) 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition
ATE382335T1 (de) * 2000-11-30 2008-01-15 Vectura Ltd Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
NZ526059A (en) * 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
DK1372608T3 (da) * 2001-03-30 2007-12-27 Jagotec Ag Medicinske aerosolformuleringer
KR20050003416A (ko) * 2002-05-07 2005-01-10 넥타르 테라퓨틱스 건조분말 흡입기용 캡슐 및 이의 제조 및 사용 방법
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
EP1861361A1 (en) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use

Also Published As

Publication number Publication date
HUS1500072I1 (hu) 2016-02-29
IL178651A0 (en) 2007-02-11
MX341426B (es) 2016-08-18
EP2422766A2 (en) 2012-02-29
DK2422766T3 (da) 2015-08-31
IL178651A (en) 2012-12-31
JP2012031209A (ja) 2012-02-16
ES2388289T3 (es) 2012-10-11
JP2007535522A (ja) 2007-12-06
HK1167334A1 (en) 2012-11-30
SG152292A1 (en) 2009-05-29
SI1755555T1 (sl) 2012-10-30
RU2006142322A (ru) 2008-06-20
CY2013012I2 (el) 2015-08-05
KR101287919B1 (ko) 2013-07-18
EP2422767A2 (en) 2012-02-29
CA2563760C (en) 2013-07-02
RU2396943C2 (ru) 2010-08-20
CN1964700A (zh) 2007-05-16
BRPI0510500A (pt) 2007-10-30
HUE025463T2 (en) 2016-02-29
ZA200609350B (en) 2008-04-30
SG10201605001SA (en) 2016-08-30
CY2015060I1 (el) 2020-05-29
NZ550479A (en) 2009-11-27
CY1116655T1 (el) 2017-03-15
LU92176I9 (no) 2019-01-04
CY2013012I1 (el) 2015-08-05
EP1755555A2 (en) 2007-02-28
PT2422766E (pt) 2015-10-12
WO2005105043A2 (en) 2005-11-10
GB0409703D0 (en) 2004-06-02
JP5124718B2 (ja) 2013-01-23
EP2422766B1 (en) 2015-06-24
AU2011200543A1 (en) 2011-03-03
IL223545A0 (en) 2013-02-03
SI2422766T1 (sl) 2015-10-30
AU2011200543B2 (en) 2012-11-29
IL223545A (en) 2016-04-21
LU92176I2 (fr) 2013-05-27
BRPI0510500B1 (pt) 2019-04-24
EP1755555B1 (en) 2012-05-23
CN102008453A (zh) 2011-04-13
HK1095282A1 (en) 2007-05-04
CA2563760A1 (en) 2005-11-10
EP2422767A3 (en) 2012-04-25
PL1755555T3 (pl) 2012-11-30
US20080063719A1 (en) 2008-03-13
ES2546982T3 (es) 2015-09-30
JP5000483B2 (ja) 2012-08-15
HUS1500073I1 (hu) 2016-02-29
DK1755555T3 (da) 2012-08-20
HUS1300006I1 (hu) 2016-07-28
AU2005237266A1 (en) 2005-11-10
KR20070033978A (ko) 2007-03-27
AU2005237266B2 (en) 2010-11-11
AU2011200543A8 (en) 2011-03-31
CN107252423A (zh) 2017-10-17
PL2422766T3 (pl) 2015-11-30
LU92392I2 (fr) 2015-11-02
CY1113069T1 (el) 2015-08-05
CY2014015I2 (el) 2015-12-09
MXPA06012493A (es) 2007-01-29
LTC2422766I2 (lt) 2020-02-10
CY2015059I1 (el) 2020-05-29
SG186673A1 (en) 2013-01-30
WO2005105043A3 (en) 2006-05-04
CY2014015I1 (el) 2015-12-09
BRPI0510500B8 (pt) 2021-05-25
PT1755555E (pt) 2012-08-17
EP2422766A3 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
NO20065502L (no) Farmasoytiske sammensetninger.
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20076046L (no) Bindemidler
ZA200709691B (en) N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
TW200519089A (en) Biaryl sulfonamides and methods for using same
NO20071823L (no) Testosterongeler omfattende polypropylenglykol som gjennomtrengningsforsterker
DE602004010164D1 (de) Capsaicinderivate und deren produktion und verwendung
TW200519100A (en) Biaryl sulfonamides and methods for using same
ZA200802848B (en) Potassium channel inhibitors
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
IS8212A (is) Nýjar 8-aza-bísýkló[3.2.1]oktanafleiður og notkunþeirra sem mónóamín-taugaboðefnaendurupptökuhindrar
NO20091990L (no) Substituerte pyrazoler, sammensetninger inneholdende disse, fremgangsmate for fremstilling og anvendelse
EA200801414A1 (ru) Кальцилитические соединения
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
DK1594868T3 (da) 8-aza-bicyclo[3.2.1]octanderivater og anvendelse deraf som monoamin-neurotransmitter-genoptagelsesinhibitorer
NO20080409L (no) Fremgangsmater og preparater til malsoking av IFNAR2
EA200701688A1 (ru) Замещённые пирролы, содержащие их композиции, способ получения и применение
WO2005120200A3 (en) Amine compounds and inhibiting neurotransmitter reuptake
ITMI20040146A1 (it) Ibopamina maleato metodo per prepararlo e composizioni farmaceutiche che lo comprendono

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application